Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM).
Zacchino M et al. Eur Radiol. 2015 May 20. [Epub ahead of print].

Global hypomethylation in myeloma is associated with poor prognosis.
Sive JI et al. Br J Haematol. 2015 May 26. doi: 10.1111/bjh.13506. [Epub ahead of print].

Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
Vagnoni D et al. Br J Haematol. 2015 May 26. doi: 10.1111/bjh.13484. [Epub ahead of print].

Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.
Moustafa MA et al. Leukemia. 2015 May 12. doi: 10.1038/leu.2015.118. [Epub ahead of print].

Decreased level of phosphatidylcholine (16:0/20:4) in multiple myeloma cells compared to plasma cells: a single-cell MALDI-IMS approach.
Hossen MA et al. Anal Bioanal Chem. 2015 May 10. [Epub ahead of print].

Progression from light chain myeloma to secondary plasma cell leukemia accompanied by peripheral blood eosinophilia.
Robier C et al. Clin Chem Lab Med. 2015 May 7. pii: /j/cclm.ahead-of-print/cclm-2015-0232/cclm-2015-0232.xml. doi: 10.1515/cclm-2015-0232. [Epub ahead of print].

Prediction of central venous catheter-related bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS).
Schalk E et al. Ann Hematol. 2015 May 3. [Epub ahead of print].

High incidence of intact or fragmented immunoglobulin in urine of patients with multiple myeloma.
Kraj M et al. Leuk Lymphoma. 2015 May 13:1-9. [Epub ahead of print].